ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.01
0.00%
US Tech 100
18,985.20
0.40%
S&P 500
5,614.56
-2.70%
US Dollar vs CAD
1.44063
-0.17%
Bitcoin
81,682.76
4.08%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Capricor Therapeutics Inc (CAPR) Share Price

Capricor Therapeutics Inc

Capricor Therapeutics Inc (CAPR)

Caprock Mining Corp
12.34
-0.47
(-3.67%)
Closed March 10 3:00PM
Delayed by 15 minutes
12.34
0.00
( 0.00% )
Pre Market: 3:53AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
12.34
Bid
12.01
Ask
12.82
Volume
100
0.00 Day's Range 0.00
3.52 52 Week Range 23.40
Market Cap
561.099M
Previous Close
12.34
Open
-
Last Trade
35
@
12.83
Last Trade Time
03:00:00
Financial Volume
-
VWAP
-
Average Volume (3m)
1,146,631
Shares Outstanding
45,469,908
Dividend Yield
-
PE Ratio
-25.17
Earnings Per Share (EPS)
-0.49
Revenue
25.18M
Net Profit
-22.29M

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.capricor.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Capricor Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CAPR. The last closing price for Capricor Therapeutics was US$12.34. Over the last year, Capricor Therapeutics shares have traded in a share price range of US$ 3.52 to US$ 23.40.

Capricor Therapeutics currently has 45,469,908 shares outstanding. The market capitalization of Capricor Therapeutics is US$561.10 million. Capricor Therapeutics has a price to earnings ratio (PE ratio) of -25.17.

Ask ADVFN Intelligence (AI)

Capricor Therapeutics (CAPR) Options Flow Summary

CAPR Options Flow

Overall Flow

Bullish

Net Premium

176k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

CAPR Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 05 2025
CAPR (-3.67%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 04 2025
CAPR (-3.67%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 04 2025
CAPR (-3.67%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 04 2025
CAPR (-3.67%)

Form 8-K - Current report
Edgar (US Regulatory)
March 04 2025
CAPR (-3.67%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 28 2025
CAPR (-3.67%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.04-19.765929778915.3816.1712224150313.17774361CS
4-1.61-11.54121863813.9516.46512152257714.2630687CS
12-1.44-10.449927431113.7816.46512114663114.08975443CS
268.08189.6713615024.2623.44.05233346614.44811095CS
526.23101.9639934536.1123.43.52133851113.09833692CS
1568.12192.4170616114.2223.42.6855418911.3871976CS
26011.311098.058252431.0323.40.889563047.98378752CS

CAPR - Frequently Asked Questions (FAQ)

What is the current Capricor Therapeutics share price?
The current share price of Capricor Therapeutics is US$ 12.34
How many Capricor Therapeutics shares are in issue?
Capricor Therapeutics has 45,469,908 shares in issue
What is the market cap of Capricor Therapeutics?
The market capitalisation of Capricor Therapeutics is USD 561.1M
What is the 1 year trading range for Capricor Therapeutics share price?
Capricor Therapeutics has traded in the range of US$ 3.52 to US$ 23.40 during the past year
What is the PE ratio of Capricor Therapeutics?
The price to earnings ratio of Capricor Therapeutics is -25.17
What is the cash to sales ratio of Capricor Therapeutics?
The cash to sales ratio of Capricor Therapeutics is 22.29
What is the reporting currency for Capricor Therapeutics?
Capricor Therapeutics reports financial results in USD
What is the latest annual turnover for Capricor Therapeutics?
The latest annual turnover of Capricor Therapeutics is USD 25.18M
What is the latest annual profit for Capricor Therapeutics?
The latest annual profit of Capricor Therapeutics is USD -22.29M
What is the registered address of Capricor Therapeutics?
The registered address for Capricor Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Capricor Therapeutics website address?
The website address for Capricor Therapeutics is www.capricor.com
Which industry sector does Capricor Therapeutics operate in?
Capricor Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AWHAspira Womans Health Inc
US$ 0.3899
(96.92%)
64.14M
TSVT2seventy bio Inc
US$ 4.94
(76.43%)
431.02k
SNOASonoma Pharmaceuticals Inc
US$ 4.41
(58.06%)
6.64M
TNONTenon Medical Inc
US$ 1.86
(48.80%)
9.97M
ADTNADTRAN Holdings Inc
US$ 11.49
(35.34%)
42
MBXMBX Biosciences Inc
US$ 5.01
(-44.21%)
2
JANXJanux Therapeutics Inc
US$ 20.05
(-33.65%)
40
SVRASavara Inc
US$ 2.01
(-24.44%)
4
SNCRSynchronoss Technologies Inc
US$ 6.01
(-22.45%)
3
XXII22nd Century Group Inc
US$ 1.58
(-21.39%)
6
AWHAspira Womans Health Inc
US$ 0.3899
(96.92%)
64.14M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.73
(4.74%)
18.96M
BTOGBit Origin Ltd
US$ 0.5074
(6.80%)
14.27M
CUTRCutera Inc
US$ 0.1475
(14.79%)
10.43M
TNONTenon Medical Inc
US$ 1.86
(48.80%)
9.97M

CAPR Discussion

View Posts
ed3/6me ed3/6me 2 days ago
Nbd
👍️0
GreedyAgorist GreedyAgorist 3 days ago
Sorry, I could have sworn earnings were Wednesday last week, but they are this coming week, 3/12 after hours. Did one or two brokers lead me astray? Or was I looking at Rigetti or some other speculative play on my watchlist and got confused? Anyway…

Last week we did get some corporate stuff, some Form 4’s and an 8K, but no earnings yet. I thought the wild swings were in response to a quarterly report, and the worst of it was over, but no such luck.

Well, if it drops to 12, I will sell a 10 for April. Good luck to all.

And condolences to anyone who loses somebody over this stupid DST nonsense. When exactly does the making ourselves healthy again start? Certainly not this weekend.
👍️0
ed3/6me ed3/6me 5 days ago
can live with price short term. and hope they finally get going toward some kind of goal
👍 1
ed3/6me ed3/6me 6 days ago
Thanks. Will pay better attention next time 
👍️0
GreedyAgorist GreedyAgorist 6 days ago
You realize that earnings is today after hours. No doubt they will post a loss, as we are not at the point of having positive revenue yet, but just need to not disappoint.

Well, at least if you bought today, that is better than the recent top when it was 30% more expensive.

Still two and a half weeks until March contracts expire. A risk taker would position today, not wait until tomorrow, after the report. How brave am I feeling?
👍️0
ed3/6me ed3/6me 6 days ago
Jumped back in. Hope it helps me
👍️0
GreedyAgorist GreedyAgorist 4 weeks ago
Wow, I hardly ever perfectly time the bottom, but I sold a cash covered put today when it was red, and before I could second guess my play, it was green and up more than two bucks.

Any explanation for the 12% gain?

Oh, well, we were here ten days ago. Nothing to get excited about, right?
👍️0
Mr.Mister Mr.Mister 2 months ago
With BLA submission in late December, when would the FDA have to accept or reject their application by? Late February?
👍️0
Volcano Volcano 2 months ago
Breaking out now
Get ready for $70 upon FDA approval
💯 1 🔥 1
Volcano Volcano 2 months ago
Price target $70-$100 upon FDA approval in a few months
Multi millionaire soon to be
👍 1
XWAVXALMIMAN XWAVXALMIMAN 2 months ago
We got the news. We finished the submission and got $10 million. People are so impatient. I’ve waited 4 1/2 years. I can wait 6-9 months for approval. Families and patients should be pushing for a much quicker approval. 30-40 in 2025.
👍️0
D-bol D-bol 2 months ago
Maybe news tomorrow
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
My question to you CAPR folks who are likely more versed than I. Is after the submission is sent to FDA for approval (in your case Deramiocel (CAP-1002)) - How long does it take FDA to make a decision on average?

I am following another company MNMD that is in Phase 3 right now for LSD that got FDA Break Through Designation.
👍️0
GreedyAgorist GreedyAgorist 3 months ago
Guess I was wrong about the new 5. It is not 20 or 17.50. Not yet. Those were the pump prices. If the pump is over for now, we might hang out around 12.50 for a while, making puts at 12.50 and 10 interesting. Likewise calls at 15 might be worth a shot. Although my next play is targeting March 17.50. If it gets there early, that will inform my next move.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 3 months ago
You’ll be sorry. Definitely an easy double from here within a year. I’ve held most shares for 4 1/2 years. Be patient. Linda sounded great - listened to interview last night after 12 days in Puerto Vallarta
👍️ 1
Laster Laster 3 months ago
Got out yesterday afternoon before that huge dump.
It looked like it wanted to drop below $16.
Crazy AH trading down to $11 and back to $16.
Concern about one of their investigators.
Either way, I am out and hope others can make a better trade than I did. Now moving my money to other more quality stocks. JMO.
👍️0
D-bol D-bol 3 months ago
What a day. Still not selling.
👍️0
PonkenPlonken PonkenPlonken 3 months ago
RFK is irrelevant to how CAPR moves.

Everything is in the price here... plus a lot of birds in the bush. Why anyone would hold this stock AFTER it all happened, no catalyst on the horizeon. Presentation roadmap ends at "today".... is clear indication they know nothing will happen for a good year or two. So it will need a breather - which I believe you see in the chart.

Bios run towards events - not because of them.
GL
👍️0
Laster Laster 3 months ago
Thank you. I have patience and can wait for mid 2025.
The problem is the biotech sector. It has gotten destroyed since Trump picked RFK Jr. as HHS secretary. Hopefully it will recover if RFK Jr. somehow doesn’t get the job.
Just hate the BS manipulation to drop stocks on no news. The stock market is a joke. Many Stocks now move on no news. I have seen stocks move from $1 to $10 on nothing. How is that possible or legal?
Just hope it doesn’t drop lower than $15. Then I might have to throw in the towel and move on.
👍️0
PonkenPlonken PonkenPlonken 3 months ago
This stock trades on a lot of hopes, dreams and "ifs".
Not unlikely that whatever they announce, it will be a sell on news event.
It believe it has to cool off until the PDUFA which is ca 1 year away.
When the roadmap a company gives in their presentation ends with "today"...... is usually not a good sign. That is speaking in terms of PPS. For the company, everything is well and funding wont be an issue.
👍️0
Laster Laster 3 months ago
Now down to $17.50. WOW. I can only guess people were expecting news on the BLA submission.
Maybe they are getting financing through the ATM and selling into the market.
Either way, this doesn't look good today.
👍️0
Laster Laster 3 months ago
This stock is ridiculous. I don't know if it is manipulation or MMs getting the stop losses?
Opened at $19.44 and then in 1 minute it went to $20.75 and then the next minute it is down to $18.92.
Clearly, someone continues to keep this below $20. When will they be done????
This is criminal IMO. I am holding because I think it makes a run to $30 once all this crap is over.
MACD histogram on the daily is going to turn positive today.
JMO.
👍️0
Laster Laster 3 months ago
The stock chart looks interesting. The MACD histogram is ready to turn positive.
The stock found support at the 25 day moving average.
PnF chart clearly shows double/triple top breakout past $21.
Nice flag forming. Needs volume to move past $20.
I think the stock will need BLA news to get the volume to move past $20.
I am looking for $30-$40 by mid 2025.

FYI. Conferences this week and next week.
Perfect time to release some updates.
👍 1
Laster Laster 3 months ago
Well yesterday sucked. Moved BACK to $20 again only to get dumped back down to $19.
Looks like it will need significant volume to move back above $20.
2 conferences in early to mid December might help.
Happy Thanksgiving.
👍️0
Laster Laster 3 months ago
I am looking for a firm break past $20 before end of the year.
I am hopeful for continued movement early 2025.
I like stocks that hold up well during sector selloff.
JMO.
👍️0
Laster Laster 3 months ago
Holding up well in bad biotech market right now.
Break $20 and this could get Interesting.
👍️0
Mionaer1 Mionaer1 4 months ago
https://d1io3yog0oux5.cloudfront.net/_a2273a855b16264d98c228e2a432c4ee/capricor/news/2024-11-20_Capricor_Therapeutics_Granted_Orphan_Drug_and_301.pdf

Great news.
👍️0
Mionaer1 Mionaer1 4 months ago
Trading range $17-22 IMO. When BLA ready (end of 2024) $30 IMO.
👍️ 1
ed3/6me ed3/6me 4 months ago
Thought it would've 17 so close. Only have pennies so can't buy much but figure the next level and 23/24. Down to 19/20 then bumping up past 30
👍 1
GreedyAgorist GreedyAgorist 4 months ago
Looks like you nearly nailed that floor price.

So, the first reaction to the quarterly numbers makes sense: down on still no P/E ratio (i.e., negative earnings). And then a bounce, presumably thanks to bargain hunters who think that if 20 is a bargain, then 17 is a steal.

We seem to be settling in price-wise. It's not just FOMO* up like last month, although we can, with some regularity, still get 10-15% swings either way to keep it interesting. For options traders like me, who, before the FDA/BLA news, have been buying under 5 and selling covered calls (mostly at 5, with the occasional 7.5 thrown in there) the only question is: What is the new 5? 20 or 17.50?

*with a little BTFD mixed in
👍️0
Laster Laster 4 months ago
Excellent that $21 support held. I was nervous for a little bit.
Now let’s break $22.50 so we can have clear sailing to $30 with target $35.
I am confident (sort of) that this will occur.
Here’s hoping.
👍 1
Laster Laster 4 months ago
Failed $22.50 break multiple times.
Probably time to consolidate before next run.
Might drop and find support at $19.50.
Hopefully not.
Still looking and hoping for volume to power this past $22.50 for good.
👍️0
Laster Laster 4 months ago
The stock chart is showing a nice ascending triangle from Sept 30th breakout from $10.
Using my novice chart skills, I get a target of $35 for the stock (flag pole from $10 to resistance at $22.50 = $12.50).
$22.50 plus $12.50 = $35. Sounds good to me.
Lower trendline has shown nice support but if the stock moves back to $20 then stock might drop back to $17.50.
Let’s what happens this week.
Hoping for move to $25 if the market looks good.
👍️0
staynafloat staynafloat 4 months ago
I think what helped the most is that the OS is only 44.7 Mil. with that added in. It appears that a lot of traders are holding making it trade very thin.

LOL ... I've been waiting for almost 5 years for this to go thru all the trials and testing and it sure is sweet :)
👍️0
GreedyAgorist GreedyAgorist 4 months ago
That dilution went about as well as any I’ve seen. The news did not even bring us below 18 for more than a wick or two. Correct me if I’m wrong, but the underwriters made out quite well, at least an extra dollar per additional share issued (~5M). Nice work if you can get it.
👍️0
Laster Laster 4 months ago
Sounds good.
Hopefully yesterday was a technical sell off to show $20 support level.
Maybe get rid of those low hanging stop loss orders.
I am not worried about another financing so I expect a nice move to $25 then $30 by EOY.
Enjoy.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 5 months ago
No comment on Blackrock report owning over 5% of Capricor?
30 will be here soon. Maybe a short squeeze will pop us up to 40
👍️0
Laster Laster 5 months ago
You never know but these $20 stocks tend to move to $25 or even $30.
I wouldn’t mind a nice 25% profit here.
👍️0
Volcano Volcano 5 months ago
The small float is getting locked up by big boys everyday
My prediction $30 by Thanksgiving and $50 by Christmas and $100 upon FDA approval in early next year
Thus became the millionaire stock indeed
👍️0
Mionaer1 Mionaer1 5 months ago
Piper Sandler PT $35

Piper Sandler analyst Edward Tenthoff initiates coverage on Capricor Therapeutics (NASDAQ: $CAPR) with an Overweight rating and a price target of $35.00.

The analyst comments: "Capricor is developing deramiocel (CAP-1002) to treat cardiomyopathy in Duchenne Muscular Dystrophy (DMD) boys. In the Phase II HOPE-2 trial (N=20), deramiocel slowed LVEF decline by 107% vs. placebo at 12 months. (p=0.002) At World Muscle Society, HOPE-2 OLE data showed deramiocel achieved an 8.1 point improvement in median LVEF and 11.0ml/m2 benefit in median End Systolic Volume vs. external controls at 2 years with benefit maintained out to 3 years. Capricor has begun the rolling BLA submission, and deramiocel could gain FDA approval for DMD cardiomyopathy in 2H:25. Deramiocel is partnered globally with Nippon Shinyaku with Capricor retaining 30-50% of potential blockbuster revenues, plus up to $1.5 billion in milestones. Capricor recently issued 5.1 million shares at $17 raising gross proceeds of $86 million, bringing pro forma cash to ~ $198 million excluding 3Q:24 burn."
👍️0
ed3/6me ed3/6me 5 months ago
time will tell
👍️0
Mionaer1 Mionaer1 5 months ago
$12? Never. $17 is the new floor IMO.
👍️0
ed3/6me ed3/6me 5 months ago
My thought is slide back to 12-15 then move to 21-25. Dip again then about 20%up. Never straight unless flooring news
👍️0
Volcano Volcano 5 months ago
This beast will keep moving up in the coming days
FDA approval is guaranteed and secured huge fund
I expect $50 by Christmas and $100 next year
I am a millionaire here
👍️0
GreedyAgorist GreedyAgorist 5 months ago
Looks like they are not even asking enough for them.

"Capricor Therapeutics (CAPR) said Thursday that it priced an underwritten offering of about 4.4 million shares at $17 per share..."

I knew the dilution was coming. I guess I was hoping that news would be later, not this week. Like the earnings report that will be a negative number (but not as negative as last quarter).

Dips are buying opportunities, but when they are based on fundamental rules of supply and demand, I wonder if there is a hurry any more. Need to know what the new plateau is. Again, I guess it was too much to ask for that to be established after this week.

: - }
👍️0
XWAVXALMIMAN XWAVXALMIMAN 5 months ago
It looked like we would hold at 20. Then they diluted our shares. I hate when that happens. Didn’t they have enough cash to survive until we would be profitable? Hopefully good news is coming and that extra money will be used for growth
👍️0
GreedyAgorist GreedyAgorist 5 months ago
Arrgghh, they could not wait to dilute, huh? I just needed a couple more days.

Feels like somebody got the info early, too. I have to wonder what price they are getting. Today's high? The after hours' low?
👍️0
ed3/6me ed3/6me 5 months ago
They sell today? Would be another k in your pocket
👍️0
XWAVXALMIMAN XWAVXALMIMAN 5 months ago
Great day today. We started out down and then reversed and had trouble getting thru 20. Since I was having eye surgery today, I put in to sell 7250 shares at 20.20. It looked good for a while when we went down to low 19’s. I tried to buy back at 18.65 but never got there. This was my 3rd time selling and buying back and selling again. I’m done. Keeping my 40.000 shares until we get to 30-40.

We ran up to 23.40 before some profit taking. Some of you are looking for a 10% correction. I use Fibonacci numbers / Elliott Wave.
We went from 4 to 22 which is 18 and then went down to around 15; a 7 point retracement. 7/18 is around 38%.

Next Wave took us from 15 to 23+. Going up 8 points means that selling should take us down 3. Expect support at 20 before the next big up move.Have a great week. Let’s Go Mets and Guardians!
👍️0
D-bol D-bol 5 months ago
DRUG We need a move like this one today!!
👍️0

Your Recent History

NASDAQ
CAPR
Capricor Therapeutics
NASDAQI
ADREM
BLDRS Emerging Markets 5...
BOV
FNAM11
Fundo Invest Amazonia Fi...
BIT
CLOU
Global X Cloud Computing...
AQSE
ASHR.GB
Deutsche Bank Luxembourg
BIT
1NEM
Newmont
BIT
NSCIT00012F7
Kingdom of Spain
BIT
NSCIT0553411
Italy
BIT
NSCIT7607756
Agricultural Pension Bank
BIT
NSCITOTE5OE7
Portugal 0637
BOV
GFSA3
GAFISA ON
BIT
NSCIT0554740
Italy
BOV
S2MA34
Smartsheet
BOV
MTSA4R
METISA PN
BIT
F28946
Vontobel Financial Produ...
BIT
3STS
Graniteshares 3x Short T...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads